BioBridgeX
Log inCompare quotes
Indication

Metabolic / Endocrinology CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a metabolic or endocrine program means matching a CRO or CDMO to the disease biology: diabetes, obesity, NASH, dyslipidemia, thyroid, and rare endocrine disorders. The work spans target validation, DIO and db/db mouse models, glucose clamps, GLP-1 and incretin pharmacology, peptide and biologic manufacturing, and clinical trials. On BioBridgeX, buyers source and compare vetted suppliers free, then contract directly with the supplier they choose.

Metabolic / Endocrinology CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Metabolic / Endocrinology CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does a Metabolic / Endocrinology program need?

Metabolic and endocrine programs cover a wide span of biology, and the CRO work changes a lot depending on where you sit in it. A type 2 diabetes or obesity asset, a NASH (now MASH) candidate, a dyslipidemia drug, a thyroid or adrenal program, and a rare endocrine disorder all share some plumbing but ask different questions of a supplier. What ties them together is a heavy reliance on in vivo disease models and a set of physiology readouts that a generalist lab often does not run well, so therapeutic-area depth matters more here than in some other areas.

On the discovery side the work usually starts with target validation and pharmacology in the standard metabolic model toolkit. Diet-induced obese (DIO) mice, db/db and ob/ob mice, Zucker and ZDF rats, streptozotocin-induced diabetes, and high-fat or methionine-choline-deficient diet models for steatohepatitis are the usual workhorses. The readouts are where indication expertise shows: oral and intraperitoneal glucose tolerance tests (OGTT, IPGTT), insulin tolerance tests, hyperinsulinemic-euglycemic clamps (the gold standard for insulin sensitivity and a genuinely hard procedure to run cleanly), body composition by EchoMRI or DEXA, indirect calorimetry for energy expenditure, HbA1c, lipid panels, and food-intake and body-weight tracking over weeks. For NASH you add liver histology with NAS and fibrosis staging, often read by a blinded pathologist, plus emerging non-invasive markers. A lot of the field now runs on incretin biology, so a CRO comfortable with GLP-1, GIP, glucagon, amylin, and dual or triple agonist pharmacology, including PK/PD around peptide half-life and receptor selectivity, is worth seeking out.

Many of these molecules are peptides, antibodies, or other biologics, which pulls CDMO capability into the picture early. That means peptide synthesis or recombinant expression, formulation work for stability and injectability (and increasingly oral peptide delivery), lyophilization, fill-finish, and the analytical methods to support them. On the safety and clinical side you will need IND-enabling tox, then clinical execution that understands endocrine endpoints and the regulatory expectations: cardiovascular outcome considerations for diabetes drugs, glycemic endpoints like HbA1c reduction, weight-loss percentage endpoints for obesity, and the FDA and EMA history around this class. Diabetes and obesity trials also run large and long, so patient access, endocrinology site networks, and central-lab capacity for metabolic assays become real selection criteria.

How do you choose a CRO for Metabolic / Endocrinology?

The screening question is fit to your specific indication and modality, not whether the supplier has a metabolic page on its website. A lab that runs beautiful DIO obesity studies may have never validated a clamp; a NASH histology specialist is the wrong first call for a thyroid program. Put two or three suppliers against the same written scope and work the checklist below before you weigh price.

  • Therapeutic-area experience: ask for relevant programs in your exact indication (diabetes, obesity, NASH/MASH, dyslipidemia, thyroid or adrenal, rare endocrine) and for the named scientists who would run your work, not just a company track record.
  • Disease models and procedures: confirm they actually run the models and readouts you need in-house (DIO, db/db, ZDF, STZ, NASH diet models, OGTT/IPGTT, clamps, indirect calorimetry, body composition) rather than subcontracting the hard parts.
  • Incretin and modality fit: for the current wave of GLP-1, GIP, glucagon, and amylin assets, check real experience with peptide and biologic PK/PD, receptor selectivity, and dosing schedules; for CDMO work, confirm peptide or biologic manufacturing, formulation, and stability capability.
  • Endpoint and histology quality: for NASH, ask who reads the liver histology and whether scoring is blinded and consistent; for clamps and calorimetry, ask for QC data and historical variability, since these procedures are easy to run badly.
  • Regulatory track record: look for prior IND/CTA packages and clinical work in this class, plus awareness of cardiovascular safety expectations for diabetes drugs and the agency history around weight and glycemic endpoints.
  • Clinical capacity and patient access: for trials, confirm endocrinology and primary-care site networks, recruitment realism for large long-running studies, and central-lab capability for HbA1c, lipids, and metabolic biomarkers.
  • Data quality and capacity: documented SOPs, traceable raw data, GLP status where the study supports a filing, and an honest read on current queue and turnaround so a booked-solid lab does not quietly become your timeline risk.

Frequently asked questions

What disease models do CROs use for metabolic and diabetes studies?
The standard toolkit covers diet-induced obese (DIO) mice for obesity and metabolic syndrome, db/db and ob/ob mice for type 2 diabetes driven by leptin-pathway defects, Zucker and Zucker Diabetic Fatty (ZDF) rats, and streptozotocin (STZ) induction for beta-cell loss and a more type 1-like picture. For steatohepatitis, high-fat diet variants, the methionine-choline-deficient diet, and newer GAN or AMLN diets are common, often with histology endpoints. The right model depends on your mechanism: an insulin-sensitizer, a GLP-1 agonist, and a fibrosis-targeted NASH drug are not all best tested in the same animal, so scope the model choice with the supplier up front.
Which readouts and endpoints matter most in metabolic pharmacology studies?
For glucose handling: OGTT and IPGTT, insulin tolerance tests, fasting glucose and insulin, HbA1c over longer studies, and the hyperinsulinemic-euglycemic clamp when you need a rigorous insulin-sensitivity measure. For obesity and energy balance: body weight, food intake, body composition by EchoMRI or DEXA, and indirect calorimetry for energy expenditure and substrate use. For dyslipidemia: full lipid panels and lipoprotein analysis. For NASH/MASH: liver histology with NAFLD activity score and fibrosis staging, ideally read blinded, plus liver enzymes and non-invasive markers. Clamps and calorimetry are the procedures most often done poorly, so ask for QC and variability data.
Do I need a CRO that specializes in GLP-1 and incretin drugs?
If your asset is in or near the incretin space, yes, specialist experience pays off. GLP-1, GIP, glucagon, and amylin pharmacology has real subtlety: receptor selectivity, dual and triple agonist balance, peptide half-life and the chemistry used to extend it, dosing schedules, and species differences in response. A CRO that has actually run these programs will design cleaner PK/PD studies and interpret the results better than a generalist. Many of these molecules are also peptides or biologics, so look for a partner (or paired CDMO) comfortable with peptide synthesis, formulation, and injectable or oral delivery, not just the in vivo pharmacology.
What should I look for in a CRO for a NASH or MASH program?
Histology quality is the center of gravity. Ask who reads the liver sections, whether scoring (NAS or SAF and fibrosis stage) is blinded and consistent across a study, and how they handle inter-reader variability, since this drives the primary endpoint in most NASH work. Confirm which diet or genetic models they run and how well those models reproduce human fibrosis, which is a known weak spot in the field. On the clinical side, the regulatory bar here has been a moving target, so a CRO that has tracked the FDA and EMA endpoint discussions and run recent MASH trials is worth more than a lower bid from a lab new to the indication.
How does BioBridgeX work, and what does it cost a buyer?
BioBridgeX is a neutral marketplace for preclinical and clinical outsourcing across all indications and modalities, including metabolic and endocrinology. You can self-serve: browse and compare vetted CROs and CDMOs, shortlist by capability, and request scopes. It is free for buyers. You compare quotes and contract directly with each supplier you choose, all in one place, and BioBridgeX takes a flat 2% fee on the supplier side. That keeps your procurement and legal overhead down when a metabolic program needs several specialists at once.
Can one supplier cover both preclinical studies and manufacturing for a metabolic asset?
Sometimes, but it is common to split the work, and that is fine. Many metabolic and endocrine assets are peptides or biologics, so you may want a pharmacology CRO for the in vivo models and PK/PD, a separate group for IND-enabling tox, and a CDMO for synthesis or expression, formulation, and fill-finish. Bundling everything with one provider can simplify coordination but can also mean accepting a weaker capability in one area to keep it under one roof. On BioBridgeX you can assemble the right specialists for each piece and contract directly with each of them in one place, so you do not trade quality for procurement convenience.

Source Metabolic / Endocrinology work with one contract

Compare transparent quotes from qualified Metabolic / Endocrinology CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes